9IH8
HSV-2 postfusion glycoprotein B
9IH8 の概要
| エントリーDOI | 10.2210/pdb9ih8/pdb |
| 関連するPDBエントリー | 9Q9L 9Q9N 9Q9S |
| EMDBエントリー | 52863 52963 52965 52966 |
| 分子名称 | Envelope glycoprotein B, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose (2 entities in total) |
| 機能のキーワード | glycoprotein b, viral membrane fusion protein, herpes simplex virus 2, hsv-2, gb, viral protein |
| 由来する生物種 | Human herpesvirus 2 strain 333 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 317764.88 |
| 構造登録者 | Vollmer, B.,Mulvaney, T.,Ebel, H.,Nentwig, J.,Gruenewald, K. (登録日: 2025-02-20, 公開日: 2025-09-03, 最終更新日: 2025-10-22) |
| 主引用文献 | Vollmer, B.,Ebel, H.,Rees, R.,Nentwig, J.,Mulvaney, T.,Schunemann, J.,Krull, J.,Topf, M.,Gorlich, D.,Grunewald, K. A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2. Nature, 646:433-441, 2025 Cited by PubMed Abstract: The nine human herpesviruses, including herpes simplex virus 1 and 2, human cytomegalovirus and Epstein-Barr virus, present a significant burden to global public health. Their envelopes contain at least ten different glycoproteins, which are necessary for host cell tropism, attachment and entry. The best conserved among them, glycoprotein B (gB), is essential as it performs membrane fusion by undergoing extensive rearrangements from a prefusion to postfusion conformation. At present, there are no antiviral drugs targeting gB or neutralizing antibodies directed against its prefusion form, because of the difficulty in structurally determining and using this metastable conformation. Here we show the isolation of prefusion-specific nanobodies, one of which exhibits strong neutralizing and cross-species activity. By mutational stabilization we solved the herpes simplex virus 1 gB full-length prefusion structure, which allowed the bound epitope to be determined. Our analyses show the membrane-embedded regions of gB and previously unresolved structural features, including a new fusion loop arrangement, providing insights into the initial conformational changes required for membrane fusion. Binding an epitope spanning three domains, proximal only in the prefusion state, the nanobody keeps wild-type HSV-2 gB in this conformation and enabled its native prefusion structure to be determined. This also indicates the mode of neutralization and an attractive avenue for antiviral interventions. PubMed: 40903574DOI: 10.1038/s41586-025-09438-5 主引用文献が同じPDBエントリー |
| 実験手法 | ELECTRON MICROSCOPY (2.21 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






